Supplementary data: A value-based budget impact model for dronedarone compared with other rhythm control strategies

<b>Supplementary Table 1: Annual Rate control costs associated with AADs and Annual ablation cost associated with AADs</b><b>Supplementary Table 2: </b>Risk of LTCOs for AADs<b>Supplementary Table 3: </b>Event Risks Associated with Dronedarone vs. Rate Control + Ablation<b>Supplementary Table 4: </b>Event Risks Associated with Dronedarone vs. Ablation<b>Supplementary Table 5: </b>Event Risks Associated with Dronedarone + Rate Control vs. AADs + Rate Control<b>Supplementary Table 6: </b>Event Risks Associated with Dronedarone vs. Rate Control<b>Supplementary Table 7: </b>Event Risks Associated with Dronedarone + Ablation vs. other AADs + Ablation<b>Supplementary Table 8: </b>Event Risks Associated with Dronedarone + Rate Control + Ablation vs. AADs + Rate Control + Ablation<b>Supplementary Table 9: </b>Event Risks Associated with Dronedarone vs. Rate Control vs. Ablation<b>Supplementary Table 10: </b>Event Risks for Temporal Scenarios<b>Aim: </b>The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective. <b>Materials &amp; methods:</b> A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM). <b>Results:</b> By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.<b> Conclusion: </b>Increased dronedarone utilization demonstrated incremental cost reductions over time.<br>